苯骈吡喃肟类化合物的合成及生物活性

苯骈吡喃类钾通道启开剂作为抗高血压药物正日益引人注目。根据现有构效关系，运用经典的药物设计方法，设计合成了２８个苯骈吡喃肟类化合物。初步药理研究表明，某些化合物有一定程度的扩血管活性。     

Insulin like activity in (−) epicatechin

Summary Water extract of the bark of plant ofPterocarpus marsupium Roxb is used as an antidiabetic drug in indigenous medicine in India. (−) Epicatechin, its active principle, has been found to be insulinogenic. The presentin vitro study reports some insulin like activities of (−) epicatechin. Like insulin, (−) epicatechin stimulates oxygen uptake in fat cells and tissue slices of various organs, increases glycogen content of rat diaphragm in dose-dependent manner with corresponding increase in U¹⁴-C glucose uptake, and inhibits theophylline induced lipolysis in isolated fat pads in dose-dependent manner. Experiments on competitive binding of¹²⁵I-insulin and (−) epicatechin to liver cell plasma membrane indicate that insulin does not share binding site with (−) epicatechin. (−) Epicatechin at a concentration of up to 1 mM does not effect the release of glucagon from the isletsin vitro. Thus, (−) epicatechin has insulinogenic as well as insulin like properties. C.D.R.I. Communication no 4499.     

新的异黄酮类化合物K3—D4,K3—D5,K3—D6的分离和结构鉴定

在对基因工程链霉菌Ｋ３的研究中,我们从其发酵液中分离到Ｋ３－Ｄ４、Ｋ３－Ｄ５、Ｋ３－Ｄ６３个化合物。通过ＵＶ、ＩＲ、ＭＳ、＾１Ｈ－ＮＭＲ、＾１３Ｃ－ＮＭＲ及ＨＭＢＣ等光谱分析确定Ｋ３－Ｄ４、Ｋ３－Ｄ５、Ｋ３－Ｄ６为３个新的异黄酮类化合物,分别为４′,５,７－三羟基－３′－硝基异黄酮、４′,５,７－三羟基－３′,５′－二硝基异黄酮、４′,７－二羟基－３′,５′－二硝基异黄酮。     

苯骈吡喃类化合物的合成及其降压活性

苯骈吡喃类钾通道启开剂具有很强的血管扩张作用,可望成为较理想的抗高血压药物。为寻找活性高、毒副作用小的新型降压药,结合某些中草药有效成分的结构特征,设计合成了11个苯骈吡喃类化合物,药理初筛表明具有心血管活性。     

Characterization of the in vitro anti-inflammatory activity of AL-5898 and related benzopyranyl esters and amides

Selected ester- (AL-5898 and AL-8417) and amide-linked benzopyran analogues (AL-7538 and AL-12615) were evaluated in vitro for their ability to inhibit key enzymes/processes of the inflammatory response. AL-7538 and AL-12615 exhibited weak intrinsic cyclooxygenase inhibitory activity (IC₅₀ = 13 M, 37 M). In contrast, 5-HETE and LTB₄ synthesis in A₂₃₁₈₇-stimulated neutrophils was effectively inhibited by both ester and amide analogs (IC₅₀ = 2–3 M). While there was some indication for differing sensitivities among benzopyran esters and amides in the suppression of cytokine synthesis in stimulated U-937 cells, there appeared to be no great discrimination when assessing their effect on U-937 cell adhesion to IL-1 activated HMVEC-L cells. Inhibition of cell adhesion was concentration-dependent, with IC₅₀ values ranging between 18 M and 30 M for AL-5898. Concentration-dependent inhibition of inflammatory cytokine production (i.e., IL-1, TNF-, GM-CSF and IL-6) was also apparent in LPS-stimulated, cultured PBMC as well as in PMA/A₂₃₁₈₇ activated U-937 cells monitoring the synthesis of IL-1, IL-8, TNF-, and MCP-1. Notably, the hydrolysis products of the benzopyranyl ester, AL-5692 and (S)-6-methoxy--methyl-2-naphthaleneacetic acid, were devoid of pharmacological activity when assessed for inhibition of monocyte adhesion or IL-1 synthesis. Collectively, our data demonstrate the unique in vitro polypharmacology of a novel series of benzopyran analogs that suppress pivotal enzymes and processes in the inflammatory response.     

Synthesis and biological evaluation of 2'-oxo-2,3-dihydro-3'H- spiro[chromene-4,5'-[1,3]oxazolidin]-3'yl]acetic acid derivatives as aldose reductase inhibitors

Aldose reductase (ARL2) is the first enzyme in the polyol pathway which catalyzes the NADPH-dependent reduction of glucose to sorbitol. Its involvement on diabetic complications makes this enzyme a challenge therapeutic target widely investigated to limit and/or prevent them. On this basis, a limited series of 4-spiro-oxazolidinone-benzopyran derivatives (1-7) were synthesized to evaluate them as potential ARL2 inhibitors. The activity was determined spectrophotometrically by monitoring the oxidation of NADPH catalyzed by ALR2. Within the series of compounds, the 4-methoxy derivative 1b showed to be the most active compound, exhibiting inhibitory levels in the submicromolar range. In addition, the activity against the aldehyde reductase isoform (ARL1) was also evaluated. Unlike sorbinil (reference drug) that lack of selectivity towards the two enzyme all the tested compounds resulted to be devoid of ARL1 inhibitory activity (IC(50) > 10 μM), thus proving to be selective.     

一氧化氮供体型抗高血压药物的研究Ⅰ.C-3位具有硝酸酯和呋咱氮氧化物取代结构的苯骈吡喃类化合物的合成及其降压活性

目的:研究C-3位一氧化氮(NO)供体取代的苯骈吡喃类化合物的合成及其降压活性,寻找活性强、不良反应小的新型抗高血压药.方法:以3,4位反式苯骈吡喃为基本骨架,在C-3位通过丁二酸连接硝酸酯和呋咱氮氧化物,合成了一系列衍生物;测定目标物对KCl引起的大鼠胸主动脉条收缩的抑制作用,选择活性化合物Ⅱ1测定其经口给药对自发性高血压大鼠(SHR)尾动脉收缩压(SAP)和舒张压(DAP)的影响;采用Griess法测定目标物体外NO释放量.结果与结论:合成了16个新化合物(Ⅰ1-6;Ⅱ1-10),结构经波谱确证.大部分目标物对大鼠胸主动脉条收缩具有不同程度的抑制作用,其中Ⅱ1的抑制率与阳性药吡那地尔(PIN)相当,对SHR尾动脉SAP和DAP的抑制幅度分别为15.2%和12.5%,降压持续时间长于PIN.Ⅱ1的NO释放量为0.9μg/mL,NO释放量与目标物降压活性的关系尚待进一步研究.     

New cytotoxic benzopyrans from the leaves ofMallotus apelta

Two new benzopyrans 6-[1'-oxo-3'(R)-hydroxy-butyl]-5,7-dimethoxy-2,2-dimethyl-2H-1-benzopyran (1) and 6-[1'-oxo-3'(R)-methoxy-butyl]-5,7-dimethoxy-2,2-dimethyl-2H-1-benzopyran (2) were isolated from the leaves of Mallotus apelta Muell.-Arg., (Euphorbiaceae). Their chemical structures were elucidated by spectroscopic analyses, especially by 1 D-, 2D-NMR and MS spectra. Compound 1 was found to have strong cytotoxic effect against two human cancer cell lines as human hepatocellular carcinoma (Hep-2, IC50: 0.49 microg/mL) and rhabdosarcoma (RD, IC50: 0.54 microg/mL), while compound 2 showed moderate activity against Hep-2 cell line (IC50, 4.22 microg/mL) by in vitro assay.     

Novel benzopyran derivatives and their therapeutic applications: a patent review (2009–2016)

Introduction: The benzopyran derivatives present a wide variety of biological activity and behaviour. At the same time the benzopyran derivatives support their use as therapeutic agents for multiple diseases. Their structural characteristics correlated to physicochemical properties seem to define the extent of the biological activity.

Areas covered: This review summarizes new patents published on new benzopyran derivatives from 2009 to 2016.

Expert opinion: Many benzopyran derivatives have vivo/vitro biological responses. Their clinical evaluation will be critical to assess therapeutic utility. The compounds containing benzopyran moiety is well defined as lead compounds for design of new more promising molecules.